Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listEpirubicin hydrochloride

Epirubicin hydrochloride

Synonym(s):4′-Epidoxorubicin hydrochloride;Epidoxorubicin hydrochloride

  • CAS NO.:56390-09-1
  • Empirical Formula: C27H30ClNO11
  • Molecular Weight: 579.9802
  • MDL number: MFCD00274554
  • EINECS: 260-145-2
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
Epirubicin hydrochloride Structural

What is Epirubicin hydrochloride?

Description

Epirubicin hydrochloride is an antitumor antibiotic which is epimeric with doxorubicin a t the 4’-position of the amino sugar moiety. It has shown utility in the treatment of mammary, gastric, colorectal, pulmonary and ovarian carcinomas, as well as malignant lymphoma and melanoma and soft tissue sarcoma. It is reported to be less sardiotoxic than doxorubicin.

Description

Epirubicin is a stereoisomer of the antitumor anthracycline doxorubicin that undergoes β-glucuronidation, which partially detoxifies the dose-limiting side effects that are present with doxorubicin. Compared to doxorubicin, epirubicin is equally cytotoxic to HeLa cells (ID50s = 9 μM). When used either alone or in combination therapies, epirubicin has been shown to demonstrate high rates of complete or partial remission in various cancers including advanced ovary, lymphomas, breast, pancreas, gastric, hepatocellular carcinoma, head and neck tumors, and colorectal.

Chemical properties

Orange-Red Crystalline Solid

Originator

Erbamont (Italy)

The Uses of Epirubicin hydrochloride

Used as an antineoplastic

The Uses of Epirubicin hydrochloride

Cell-permeable anthracycline anti-tumor antibiotic

What are the applications of Application

Epirubicin Hydrochloride is a cell-permeable Topo II inhibitor

brand name

Ellence(Pfizer);FARMORUBICIN.

Biological Functions

This stereoisomer of doxorubicin has the 4′-hydroxy group of the daunosamine sugar oriented in the β-position . Epirubicin will be slowly reduced to the active C13 alcohol (epirubicinol), giving it a 30- to 38-hour half life, which is similar to that of doxorubicin. Unlike doxorubicinol, however, which was equally active with doxorubicin, epirubicinol has only one-tenth the activity of its parent drug and is not believed to contribute significantly to the therapeutic action of this agent.

Biological Activity

Antibiotic antitumor agent. Inhibits the synthesis and function of DNA (IC 50 = 62.7 μ M in rat glioblastoma cell lines) and inhibits the relaxing property of topoisomerase II.

Clinical Use

Epirubicin is indicated for use in breast cancer, and the starting dose is 100 to 120 mg/m2 (compared to a starting dose of 60–75 mg/m2 for doxorubicin).

Side Effects

The side effects and precautions are as outlined previously for doxorubicin, although there is a lower risk of serious myocardial toxicity or myelotoxicity.

Drug interactions

Potentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine - increased risk of agranulocytosis.
Ciclosporin: increased risk of neurotoxicity
Cytotoxics: possible increased risk of cardiotoxicity with trastuzumab - avoid for up to 28 weeks after stopping trastuzumab.
Ulcer-healing drugs: concentration increased by cimetidine.
Vaccines: avoid with live vaccines

Metabolism

Cleavage of the epimerized sugar will occur before excretion, generating an aglycone that is indistinguishable from that generated by doxorubicin. Although excretion is primarily biliary, dosage reduction in severe renal impairment, as well as in hepatic dysfunction, is warranted.

storage

+4°C

References

1) Cersosimo?et al. (1986),?Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue; J. Clin. Oncol.,?4?425 2) Spadari?et al. (1986),?DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs; Anticancer Res.,?6?935 3) Minotti?et al. (2004),?Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity; Pharmacol. Rev.,?56?185 4) Mercuro?et al. (2007),?Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers; Oncologist,?12?1124

Properties of Epirubicin hydrochloride

Melting point: 185°C dec.
alpha  D20 +274° (c = 0.01 in methanol)
RTECS  QI9295750
Flash point: 443.8℃
storage temp.  Inert atmosphere,Store in freezer, under -20°C
solubility  Soluble in DMSO to 100mM, or in ethanol to 10mM
form  powder
color  red to deep red
Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 3 months.

Safety information for Epirubicin hydrochloride

Signal word Danger
Pictogram(s)
ghs
Exclamation Mark
Irritant
GHS07
ghs
Health Hazard
GHS08
GHS Hazard Statements H302:Acute toxicity,oral
H340:Germ cell mutagenicity
H350:Carcinogenicity
H360:Reproductive toxicity
Precautionary Statement Codes P201:Obtain special instructions before use.
P308+P313:IF exposed or concerned: Get medical advice/attention.

Computed Descriptors for Epirubicin hydrochloride

InChIKey MWWSFMDVAYGXBV-UAOJCOQHSA-N
SMILES C12=C(O)C3=C(C(=O)C4=C(C3=O)C=CC=C4OC)C(O)=C1[C@@]([H])(O[C@H]1O[C@@H](C)[C@H](O)[C@@H](N)C1)C[C@](O)(C(=O)CO)C2.Cl

Related products of tetrahydrofuran

You may like

  • 56390-09-1 Epirubicin hydrochloride 98%
    56390-09-1 Epirubicin hydrochloride 98%
    56390-09-1
    View Details
  • 56390-09-1 98%
    56390-09-1 98%
    56390-09-1
    View Details
  • Epirubicin Hydrochloride (EPR.HCl) CAS 56390-09-1
    Epirubicin Hydrochloride (EPR.HCl) CAS 56390-09-1
    56390-09-1
    View Details
  • Epirubicin hydrochloride CAS 56390-09-1
    Epirubicin hydrochloride CAS 56390-09-1
    56390-09-1
    View Details
  • 1823368-42-8 98%
    1823368-42-8 98%
    1823368-42-8
    View Details
  • 2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%
    1307449-08-6
    View Details
  • Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%
    25408-95-1
    View Details
  • Lithium Clavulanate
    Lithium Clavulanate
    61177-44-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.